NasdaqGS:BMRNBiotechs
Should BioMarin’s Cost Cuts, Roctavian Exit, and Pipeline Shifts Require Action From BMRN Investors?
Earlier this month, BioMarin Pharmaceutical’s CEO reported that the company’s US$500 million cost transformation program is about two-thirds complete and reiterated an ambition to reach a 40% non-GAAP operating margin next year, while also reshaping the portfolio through workforce reductions and discontinuation of the Roctavian program.
At the same time, analysts have raised concerns about rising competition in achondroplasia and potential gaps in BioMarin’s pipeline, even as they...